Latest Breaking News On - Lunresertib lunre - Page 1 : comparemela.com

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

Repare Therapeutics Inc. , a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib in combination with FOLFIRI for the.